Congenital and pediatric interstitial disease.
Congenital and pediatric interstitial lung disease (ILD) is set in the context of the maturing lung and immune system, and thus differs completely from its adult equivalents in presentation, therapy, and outcome. We first establish the background by briefly reviewing normal maturational changes and then describe recent advances in diagnosis. We then highlight three specific topics: drugs and the lung (treatment and iatrogenic ILD); the histiocytic disorders of the lung; and congenital ILD (specifically congenital surfactant protein deficiency).
Bush
A
A
Department of Pediatric Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom.
du Bois
R
R
D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D015614:Histiocytosis / Q000503:physiopathology; D006801:Humans; D008168:Lung / Q000254:growth & development; D017563:Lung Diseases, Interstitial / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011663:Pulmonary Surfactants / Q000172:deficiency; D016896:Treatment Outcome
D011663:Pulmonary Surfactants